Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | RORC | P51449 | 12/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.40 |
| ▸ | CKS1B | P61024 | 1/20 | 0.40 |
| ▸ | SKP1 | P63208 | 1/20 | 0.40 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.40 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.39 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL106274 | 1.00 | MAPT (0.46) | MAPTRORCMEN1KMT2APDK2 | |
| SCHEMBL102705 | 0.96 | RORC (0.48) | MAPTRORCPDK2GPR119ENPP2 | |
| SCHEMBL103326 | 0.84 | RORC (0.46) | RORCGPR119 | |
| SCHEMBL104146 | 0.84 | RORC (0.46) | RORCGPR119 | |
| SCHEMBL104145 | 0.84 | RORC (0.46) | RORCGPR119 | |
| SCHEMBL104144 | 0.84 | RORC (0.46) | RORCGPR119 | |
| SCHEMBL102624 | 0.83 | RORC (0.41) | RORC | |
| SCHEMBL102623 | 0.83 | RORC (0.41) | RORC | |
| SCHEMBL102189 | 0.82 | KMT2A (0.48) | MAPTMEN1KMT2ACKS1BSKP1 | |
| SCHEMBL102190 | 0.82 | KMT2A (0.48) | MAPTMEN1KMT2ACKS1BSKP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2426113-B1 | CARBINOL COMPOUND HAVING HETEROCYCLIC LINKER | KOWA CO (JP) | 2013-11-06 | — | — | EP | disclosed |
| US-8551985-B2 | Carbinol derivatives having heterocyclic linker | KOWA COMPANY, LTD. (JP) | 2013-10-08 | — | — | US | disclosed |
| EP-2426113-A1 | CARBINOL COMPOUND HAVING HETEROCYCLIC LINKER | Kowa Company, Ltd. (JP) | 2012-03-07 | — | — | EP | disclosed |
| US-20100280013-A1 | CARBINOL DERIVATIVES HAVING HETEROCYCLIC LINKER | KOWA COMPANY, LTD. (JP) | 2010-11-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100280013-A1 | CARBINOL DERIVATIVES HAVING HETEROCYCLIC LINKER | NR1H2, NR1H3, CCR2 | MAPT 2589/4885RORC 19/4885MEN1 3479/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.